CN117062840A - 靶向bcma的多特异性抗体 - Google Patents

靶向bcma的多特异性抗体 Download PDF

Info

Publication number
CN117062840A
CN117062840A CN202280022841.5A CN202280022841A CN117062840A CN 117062840 A CN117062840 A CN 117062840A CN 202280022841 A CN202280022841 A CN 202280022841A CN 117062840 A CN117062840 A CN 117062840A
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
sequence shown
binding moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280022841.5A
Other languages
English (en)
Chinese (zh)
Inventor
张兵
赵伟
陆亚敏
杜敏
甄子朋
谢美娟
汪鑫
席俊晓
宋馨
杜秀贞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of CN117062840A publication Critical patent/CN117062840A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202280022841.5A 2021-04-15 2022-04-14 靶向bcma的多特异性抗体 Pending CN117062840A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021104056383 2021-04-15
CN202110405638 2021-04-15
PCT/CN2022/086842 WO2022218380A1 (zh) 2021-04-15 2022-04-14 靶向bcma的多特异性抗体

Publications (1)

Publication Number Publication Date
CN117062840A true CN117062840A (zh) 2023-11-14

Family

ID=83640152

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280022841.5A Pending CN117062840A (zh) 2021-04-15 2022-04-14 靶向bcma的多特异性抗体

Country Status (12)

Country Link
US (1) US20240182592A1 (cg-RX-API-DMAC7.html)
EP (1) EP4324853A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024516098A (cg-RX-API-DMAC7.html)
KR (1) KR20230170721A (cg-RX-API-DMAC7.html)
CN (1) CN117062840A (cg-RX-API-DMAC7.html)
AU (1) AU2022256638A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023020341A2 (cg-RX-API-DMAC7.html)
CA (1) CA3214012A1 (cg-RX-API-DMAC7.html)
IL (1) IL307308A (cg-RX-API-DMAC7.html)
MX (1) MX2023011923A (cg-RX-API-DMAC7.html)
TW (1) TW202304963A (cg-RX-API-DMAC7.html)
WO (1) WO2022218380A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4201960A4 (en) * 2020-08-20 2024-09-04 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. BCMA-BINDING SINGLE MOLECULE WITH VARIABLE DOMAIN AND ANTIGEN-BINDING MOLECULE
WO2022037527A1 (zh) * 2020-08-20 2022-02-24 正大天晴药业集团股份有限公司 结合bcma的单可变结构域及抗原结合分子
JP2026513451A (ja) * 2023-04-24 2026-04-27 正大天晴▲藥▼▲業▼集▲団▼股▲フン▼有限公司 c-Metを標的とする多重特異性抗体
CN119119246B (zh) * 2024-06-26 2025-10-10 中国农业科学院兰州兽医研究所(中国动物卫生与流行病学中心兰州分中心) 一种抗非洲猪瘟病毒k205r蛋白的纳米抗体及应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106661120A (zh) * 2014-08-04 2017-05-10 豪夫迈·罗氏有限公司 双特异性t细胞活化性抗原结合分子
CN108350076A (zh) * 2015-08-17 2018-07-31 詹森药业有限公司 抗-bcma抗体,结合bcma和cd3的双特异性抗原结合分子及其用途
JP2018161140A (ja) * 2012-04-11 2018-10-18 アメリカ合衆国 B細胞成熟抗原を標的指向するキメラ抗原受容体
CN112794916A (zh) * 2021-04-08 2021-05-14 正大天晴药业集团南京顺欣制药有限公司 三特异性抗原结合构建体及构建方法和应用
WO2022037528A1 (zh) * 2020-08-20 2022-02-24 正大天晴药业集团股份有限公司 结合bcma的单可变结构域及抗原结合分子
CN115715325A (zh) * 2020-08-20 2023-02-24 正大天晴药业集团股份有限公司 结合bcma的单可变结构域及抗原结合分子

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3896091T3 (pl) 2016-08-10 2024-04-29 Legend Biotech Ireland Limited Chimeryczne receptory antygenowe nakierowane na bcma i sposoby ich zastosowania
US11124577B2 (en) * 2016-11-02 2021-09-21 Engmab Sàrl Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
CN110891971B (zh) * 2017-06-20 2024-01-12 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
KR20200142525A (ko) 2018-04-05 2020-12-22 노파르티스 아게 암에 대한 삼중특이성 결합 분자 및 이의 용도
BR112021008486A2 (pt) * 2018-11-01 2021-10-26 Shandong New Time Pharmaceutical Co., Ltd Anticorpo biespecífico e seu uso
CN110551221B (zh) * 2019-07-02 2021-03-05 广州爱思迈生物医药科技有限公司 一种双特异性抗体及其制备方法与应用
CN112574308A (zh) * 2019-09-30 2021-03-30 和铂医药(苏州)有限公司 靶向bcma的抗体、双特异性抗体及其用途

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018161140A (ja) * 2012-04-11 2018-10-18 アメリカ合衆国 B細胞成熟抗原を標的指向するキメラ抗原受容体
CN106661120A (zh) * 2014-08-04 2017-05-10 豪夫迈·罗氏有限公司 双特异性t细胞活化性抗原结合分子
CN108350076A (zh) * 2015-08-17 2018-07-31 詹森药业有限公司 抗-bcma抗体,结合bcma和cd3的双特异性抗原结合分子及其用途
WO2022037528A1 (zh) * 2020-08-20 2022-02-24 正大天晴药业集团股份有限公司 结合bcma的单可变结构域及抗原结合分子
CN115698077A (zh) * 2020-08-20 2023-02-03 正大天晴药业集团股份有限公司 结合bcma的单可变结构域及抗原结合分子
CN115715325A (zh) * 2020-08-20 2023-02-24 正大天晴药业集团股份有限公司 结合bcma的单可变结构域及抗原结合分子
CN112794916A (zh) * 2021-04-08 2021-05-14 正大天晴药业集团南京顺欣制药有限公司 三特异性抗原结合构建体及构建方法和应用

Also Published As

Publication number Publication date
KR20230170721A (ko) 2023-12-19
EP4324853A1 (en) 2024-02-21
MX2023011923A (es) 2023-10-23
JP2024516098A (ja) 2024-04-12
WO2022218380A1 (zh) 2022-10-20
BR112023020341A2 (pt) 2024-02-06
IL307308A (en) 2023-11-01
AU2022256638A1 (en) 2023-11-09
CA3214012A1 (en) 2022-10-20
TW202304963A (zh) 2023-02-01
US20240182592A1 (en) 2024-06-06
EP4324853A4 (en) 2025-07-16

Similar Documents

Publication Publication Date Title
KR102944460B1 (ko) Cldn18.2 및 cd3에 대한 항체 작제물
TWI754800B (zh) 新型抗ox40/pd-l1雙特異性抗體分子、新型抗vegf/gitr雙特異性抗體分子及其用途
TWI858393B (zh) 介白素2突變體以及其融合蛋白
CN110229232B (zh) 双特异性抗体及其用途
US20240182592A1 (en) Multi-specific antibody targeting bcma
JP2023159379A (ja) Pd-1とvegfを標的とした四価二重特異性抗体、その製造方法および用途
JP2023550419A (ja) 二機能性分子
WO2023036215A1 (zh) 双特异性抗原结合分子及其应用
CN121079329A (zh) 靶向c-Met的多特异性抗体
KR20230098335A (ko) 클리핑 비율이 감소된 항원 결합 도메인
WO2024235317A1 (zh) 结合lilrb4和cd3的抗体及其用途
AU2024293248A1 (en) Anti-HER2 single-domain antibody, and preparation method therefor and use thereof
KR20260006599A (ko) G 단백질 결합 수용체를 표적으로 하는 이중특이성 항체
WO2025077831A1 (en) Anti-il-4ra/tslp antibodies and uses thereof
TWI894360B (zh) 抗tigit抗體及雙抗體和它們的應用
EA051272B1 (ru) Мультиспецифическое антитело, нацеленное на bcma
CN120858119A (zh) 抗muc17、cd3和cd28三特异性抗体
CN118894943A (zh) 靶向密蛋白的双特异性抗体
AU2024257454A1 (en) Anti-pd-l1 nanobody, preparation method therefor and use thereof
CN119119268A (zh) Pvrig抗体及其制备方法和应用
CN118076644A (zh) 针对免疫检查点的双特异性抗体
CN118894944A (zh) 抗密蛋白双特异性抗体
NZ762170B2 (en) Novel anti-cd3epsilon antibodies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40101521

Country of ref document: HK